Liposomalna cytarabina : to już 25 lat!

• Autorzy: Pentak, Danuta

Warianty tytułu

EN

Liposomal cytarabine : it's been 25 years!

• Języki publikacji: EN

Abstrakty

EN

The first research on liposomes took place in the mid-19th century. It was then that lecithin was isolated from egg yolk for the first time. The phenomenon of swelling of lipids in aqueous solution was then observed. This was done by Maurice Gobley. In the early 1960s, English biophysicist Alec Bangham noticed that lipids had a natural tendency to spontaneously transform into a closed, double bilayer vesicle. Bangham called the discovered structures "spherulites". In subsequent years, this name evolved through the term "banghosomes", giving today's name - liposomes. Liposomes can be carriers of various drugs, including anticancer ones.

Słowa kluczowe

PL

liposomy; cytarabina; terapia kombinowana; protokoły leczenia

EN

liposomes; cytarabine; combination therapy; treatment protocol

• Czasopismo: Wiadomości Chemiczne
• Rocznik: 2024
• Tom: [Z] 78, 5-6
• Strony: 491--505
• Opis fizyczny: Bibliogr. 42 poz.

Twórcy

autor

Pentak, Danuta

• Wydział Chemii i Farmacji, Uniwersytet Opolski, ul. Oleska 48, 45-052 Opole,

Bibliografia

• [1] A. Bangham, R.W. Horne, J Mol Biol, 1964, 8, 660
• [2] D. Romero, Nat Rev Clin Oncol, 2016, 13, 464
• [3] M. Machaczka, M. Rucińska, M. Jabłoński, Przegl Lek, 1998, 8, 407
• [4] J. Wen, Blood, 2000, 12, 3900
• [5] B.A. Parker, M. Santarelli, J Clin Oncol, 1993, 11, 248
• [6] M. Hänel, N. Kröger, M.M Hoffknecht, S.O. Peters, Ann Hematol, 2000, 79, 304
• [7] H. Nückel, J. Dürig, U. Dührsen, Ann Hematol, 2003, 82, 481
• [8] K.S. Zuckerman, J Clin Oncol, 1990, 8, 248
• [9] T. Philip, P. Biron, Eur J Cancer Clin Oncol, 1993, 19, 1371
• [10] R. Chopra, A.K. McMillan, Blood, 1993, 81, 1137
• [11] E.M. Bessell, F. Graus, J Clin Oncol, 1996, 14, 945
• [12] E.R. Gaynor, J.E. Ultmann, H.M. Golomb, J Clin Oncol, 1985, 3, 1596
• [13] C. Guglielmi, S. Amadori, M. Martelli, Leuk Lymphoma, 1992, 7, 205
• [14] R. Pettengell, G.R. Morgenstern, P.J. Woll, Blood, 1993, 82, 3770
• [15] P. Schulman, K. McCarroll, M.R. Cooper, Med Pediatr Oncol, 1990, 18, 482
• [16] L.J. Swinnen, G.M. Mullen, Blood, 1995, 86, 3333
• [17] M.J. Watts, S.J. Ings, D. Leverett, Br J Cancer, 2000, 82, 278
• [18] J. Alexandre, J Natl Cancer Inst, 2006, 98, 236
• [19] F. Spreafico, M. Massimino, R. Luksch, J Clin Oncol, 2002, 20, 2783
• [20] S. Akilesh, N. Juaire, J.S. Duffield, Am J Kidney Dis, 2014, 63, 843
• [21] P. Anderson, D. Aguilera, M. Pearson, Cancer Control, 2008, 15, 38
• [22] R. Chugh, T. Wagner, Cancer, 2007, 109, 2315
• [23] D. Iżycki, S. Nawrocki, Współczesna Onkol, 2004, 8, 124
• [24] P. Rathee, H. Chaudhary, Pharm Innov Jour, 2012, 12, 90
• [25] J.E. Mulder, J.P. Bileziskian, J Clin Densitorn, 2004, 7, 432
• [26] W. Leppert, T. Buss, Curr Pain Headache Rep, 2012, 16, 307
• [27] C.F. Thorn, C. Oshiro, S. Marsh, Pharmacogenet Genomics, 2011, 21, 440
• [28] R.L. Jones, Ch. Swanton, M. Ewer, Expert Opin Drug Saf, 2006, 5, 791
• [29] O. Tacar, P. Sriamornsak, J Pharm Pharmacol, 2013, 65, 157
• [30] A.D. Bangham, M.W. Hill, Methods in Membrane Biology, New York, 1974
• [31] F. Szoka, D. Papahadjopoulos, Proc Natl Acad Sci USA, 1978, 75, 4194
• [32] W.T. Al-Jamal, K. Kostarelos, Nanomed, 2007, 2, 85
• [33] D. Peer, J.M. Karp, S. Hong, R. Langer, Nat Nanotechnol, 2007, 2, 751
• [34] M. Ferrari, Nat Rev Cancer, 2005, 5, 161
• [35] O.V. Salata, J Nanobiotechnol, 2004, 2, 3
• [36] L. Zhang, F.X. Gu, Clin Pharmacol Ther, 2008, 83, 761
• [37] J.E. Riviere, Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009, 1, 26
• [38] A. Nagayasua, K. Uchiyama Adv Drug Deliv Rev, 1999, 40, 75
• [39] T.L. Andresen, S.S. Jensen, Prog Lipid Res, 2005, 44, 68
• [40] R.K. Jain, T. Stylianopoulos, Nat Rev Clin Oncol, 2010, 7, 653
• [41] N. Gokbuget, C.M. Hartog, R. Bassan, Haematologica, 2011, 96, 238
• [42] M. Długosz-Danecka, W. Jurczak, K. Krawczyk, Acta Haematol Pol, 2014, 45, 54

Identyfikatory

DOI

10.53584/wiadchem.2024.05.3